Photo of Deepa Rangachari, MD

Deepa Rangachari, MD

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center
Phone: (617) 667-1580
Fax: (617) 667-2518

Photo of Deepa Rangachari, MD

Beth Israel Deaconess Medical Center
Phone: (617) 667-1580
Fax: (617) 667-2518

Visualize Collaborations

Deepa Rangachari, MD

Beth Israel Deaconess Medical Center

EDUCATIONAL TITLES

  • Assistant Professor, Medicine, Harvard Medical School
  • Attending Physician, Medicine, Medical Oncology, Beth Israel Deaconess Medical Center
  • Director of Hematology/Oncology Graduate Medical Education, Medicine, Beth Israel Deaconess Medical Center

HCC PROGRAM AFFILIATION

Research Abstract

Dr. Deepa Rangachari is a medical oncologist specializing in thoracic cancers, with a particular interest in the management of patients with advanced/metastatic lung cancer through novel applications of targeted and immune therapies; she serves a member of the DFHCC Lung Cancer Program. She is additionally focused on leadership and mentorship in graduate and post-graduate medical education, with an emphasis on curriculum development and mentorship in Hematology/Oncology. She serves as the BIDMC Director of Hematology/Oncology Graduate Medical Education and Hematology/Oncology Fellowship Program Director.

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Gatof ES, Jassim SH, Ahn L, Chen ZZ, VanderLaan PA, Rangachari D. Massive Thymic Hyperplasia Masquerading as Cancer: A Case Report and Review of the Literature. JTO Clin Res Rep 2023; 4:100463. PubMed
  • Roberts DA, Faig J, Bodio-Downey K, Shpilsky J, Leahy K, Wischhusen J, Giordano S, Acharya U, Drews R, Dougherty D, Lathan C, Rangachari D. Training Hematologists/Oncologists for the Academic-Community Hybrid: Creating a Fellowship Framework for the Future. JCO Oncol Pract 2022. PubMed
  • Sentana-Lledo D, Viray H, Piper-Vallillo AJ, Widick P, Rangachari D, Wilson JL, Gangadharan SP, Aronovitz JA, Berman SM, VanderLaan PA, Costa DB. Complete pathologic response to short-course neoadjuvant alectinib in mediastinal node positive (N2) ALK rearranged lung cancer. Lung Cancer 2022; 172:124-126. PubMed
  • Piper-Vallillo AJ, Rotow JK, Aredo JV, Shaverdashvili K, Luo J, Carlisle JW, Husain H, Muzikansky A, Heist RS, Rangachari D, Ramalingam SS, Wakelee HA, Yu HA, Sequist LV, Bauml JM, Neal JW, Piotrowska Z. High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience. JTO Clin Res Rep 2022; 3:100328. PubMed
  • Patell R, Bindal P, Dodge L, Elavalakanar P, Freed JA, Rangachari D, Buss M, Schonberg M, Braun I. Oncology Fellows' Clinical Discussions, Perceived Knowledge, and Formal Training Regarding Medical Cannabis Use: A National Survey Study. JCO Oncol Pract 2022. PubMed
  • Rangachari D, Im A, Brondfield S. Moving From Theory to Practice in Oncology Education When Virtual Is Your Reality. Am Soc Clin Oncol Educ Book 2022; 42:1-10. PubMed
  • Martin RL, Grant MJ, Kimani S, Midha S, May J, Patell R, Collier E, Furfaro D, Bodine C, Reap L, Shah N, DeLaune J, Brusca S, Olazagasti C, Goyal S, Rubinstein S, Hakim N, Qin S, Browning SL, Sena L, Gilbert J, Davidson M, Lovly CM, Seetharamu N, Rangachari D, Murphy M, Chatwal M, Paschal R, Henry E, Collichio F, Green JR. Forming the Hematology-Oncology Collaborative Videoconferencing (CO-VID) Learning Initiative: Experiential Lessons Learned From a Novel Trainee-Led Multidisciplinary Virtual Learning Platform. JCO Oncol Pract 2021. PubMed
  • Sehgal K, Gill RR, Widick P, Bindal P, McDonald DC, Shea M, Rangachari D, Costa DB. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy. JAMA Netw Open 2021; 4:e2037120. PubMed
  • Kobayashi IS, Viray H, Rangachari D, Kobayashi SS, Costa DB. EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios. Cells 2021. PubMed
  • Neal JW, Costa DB, Muzikansky A, Shrager JB, Lanuti M, Huang J, Ramachandran KJ, Rangachari D, Huberman MS, Piotrowska Z, Kris MG, Azzoli CG, Sequist LV, Chaft JE. Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III -Mutant Non-Small-Cell Lung Cancer. JCO Precis Oncol 2021; 5:325-332. PubMed
  • Piper-Vallillo AJ, Halbert BT, Rangachari D, Kobayashi SS, Costa DB. Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by -D1228 and -Y1230 Mutations in -Mutated -Amplified Lung Cancer. JTO Clin Res Rep 2020; 1:100071. PubMed
  • Sehgal K, Rangachari D, VanderLaan PA, Kobayashi SS, Costa DB. Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations. Oncologist 2020. PubMed
  • Pertejo-Fernandez A, Ricciuti B, Hammond SP, Marty FM, Recondo G, Rangachari D, Costa DB, Awad MM. Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection. Lung Cancer 2020; 145:181-185. PubMed
  • Sehgal K, Bulumulle A, Brody H, Gill RR, Macherla S, Qilleri A, McDonald DC, Cherry CR, Shea M, Huberman MS, VanderLaan PA, Weiss GJ, Walker PR, Costa DB, Rangachari D. Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non-small-cell Lung Cancer. Clin Lung Cancer 2020. PubMed
  • Sehgal K, Piper-Vallillo AJ, Viray H, Khan AM, Rangachari D, Costa DB. Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond? 2020. PubMed
  • Sehgal K, Varkaris A, Viray H, VanderLaan PA, Rangachari D, Costa DB. Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized? J Immunother Cancer 2020. PubMed
  • Cooper AJ, Kobayashi Y, Kim D, Clifford SE, Kravets S, Dahlberg SE, Chambers ES, Li J, Rangachari D, Nguyen T, Costa DB, Rabin MS, Wagle N, Sholl LM, Jänne PA, Oxnard GR. Identification of a RAS-activating Fusion in an Exceptional Responder to Sunitinib with Non-Small Cell Lung Cancer. Clin Cancer Res 2020. PubMed
  • Sehgal K, Costa DB, Rangachari D. Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic? 2020; 10:1193. PubMed
  • Widick P, Gill RR, Mantia C, Costa DB, Rangachari D. Extensive-Stage Small-Cell Lung Cancer With Sustained Complete Response to Single-Agent Nivolumab and Immune-Related Dermatitis. Clin Lung Cancer 2020; 21:e6-e9. PubMed
  • Freed JA, Hale AJ, Rangachari D, Ricotta DN. Twelve tips for teaching oncology to non-oncologists. Med Teach 2019. PubMed
  • Piper AJ, Sehgal K, Costa DB, Rangachari D. Can PD-L1 tumor proportion score be used as the key to unlocking the KEYNOTE studies of pembrolizumab in advanced lung cancer? Transl Lung Cancer Res 2019; 8:715-722. PubMed
  • Farago AF, Yeap BY, Stanzione M, Hung YP, Heist RS, Marcoux JP, Zhong J, Rangachari D, Barbie DA, Phat S, Myers DT, Morris R, Kem M, Dubash TD, Kennedy EA, Digumarthy SR, Sequist LV, Hata AN, Maheswaran S, Haber DA, Lawrence MS, Shaw AT, Mino-Kenudson M, Dyson NJ, Drapkin BJ. Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer. 2019; 9:1372-1387. PubMed
  • DeLeonardis K, Hogan L, Cannistra SA, Rangachari D, Tung N. When Should Tumor Genomic Profiling Prompt Consideration of Germline Testing? J Oncol Pract 2019; 15:465-473. PubMed
  • Rangachari D, Costa DB. From Hope to Reality: Durable Overall Survival With Immune Checkpoint Inhibitors for Advanced Lung Cancer. J Clin Oncol 2019. PubMed
  • Leaf RK, Ferreri C, Rangachari D, Mier J, Witteles W, Ansstas G, Anagnostou T, Zubiri L, Piotrowska Z, Oo TH, Iberri D, Yarchoan M, Salama AKS, Johnson DB, Leavitt AD, Rahma OE, Reynolds KL, Leaf DE. Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. Am J Hematol 2019; 94:563-574. PubMed
  • Varkaris A, Sehgal K, Rangachari D, Costa DB. Complete and Sustained Response of Brain Metastases to Programmed Death 1 Antibody Monotherapy in Treatment-naive Programmed Death Ligand 1-Positive Lung Cancer. J Thorac Oncol 2019; 14:e34-e36. PubMed
  • Petri CR, Patell R, Batalini F, Rangachari D, Hallowell RW. Severe pulmonary toxicity from immune checkpoint inhibitor treated successfully with intravenous immunoglobulin: Case report and review of the literature. Respir Med Case Rep 2019; 27:100834. PubMed
  • Jorge SE, Lucena-Araujo AR, Yasuda H, Piotrowska Z, Oxnard GR, Rangachari D, Huberman MS, Sequist LV, Kobayashi SS, Costa DB. EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas. Clin Cancer Res 2018. PubMed
  • Sehgal K, Patell R, Rangachari D, Costa DB. Targeting rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors. Transl Cancer Res 2018; 7:S779-S786. PubMed
  • Sehgal K, Peters MLB, VanderLaan PA, Rangachari D, Kobayashi SS, Costa DB. Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer. J Thorac Oncol 2018. PubMed
  • Ostios-Garcia L, Faig J, Leonardi GC, Adeni AE, Subegdjo SJ, Lydon CA, Rangachari D, Huberman MS, Sehgal K, Shea M, VanderLaan PA, Cheng MP, Marty FM, Hammond SP, Costa DB, Awad MM. Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer. J Thorac Oncol 2018; 13:1037-1042. PubMed
  • VanderLaan PA, Chen Y, DiStasio M, Rangachari D, Costa DB, Heher YK. Molecular Testing Turnaround Time in Non-Small-Cell Lung Cancer: Monitoring a Moving Target. Clin Lung Cancer 2018. PubMed
  • Rangachari D, VanderLaan PA, Costa DB. Updated Correlation of 22C3-PD-L1 ≥50% Expression with Driver Oncogene Mutations and Response to Pembrolizumab in the Kinase Inhibitor-Resistant Setting. J Thorac Oncol 2018; 13:e81-e83. PubMed
  • VanderLaan PA, Rangachari D, Majid A, Parikh MS, Gangadharan SP, Kent MS, McDonald DC, Huberman MS, Kobayashi SS, Costa DB. Tumor biomarker testing in non-small-cell lung cancer: A decade of change. Lung Cancer 2018; 116:90-95. PubMed
  • Shea M, Rangachari D, Hallowell RW, Hollie NI, Costa DB, VanderLaan PA. Radiologic and autopsy findings in a case of fatal immune checkpoint inhibitor-associated pneumonitis. Cancer Treat Res Commun 2018; 15:17-20. PubMed
  • VanderLaan PA, Rangachari D, Costa DB. Lung Cancer with a High Tumor Mutational Burden. N Engl J Med 2018; 379:1093. PubMed
  • Le X, Rangachari D, Costa DB. Moving more potent and less toxic options to the frontline in the management of advanced lung cancer. J Thorac Dis 2017; 9:2812-2818. PubMed
  • Carney BJ, Rangachari D, VanderLaan PA, Gowen K, Schrock AB, Ali SM, Costa DB. De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma. Lung Cancer 2017. PubMed
  • Rangachari D, Costa DB. Moving the mountain in advanced non-small-cell lung cancer: evolving immunotherapies for a dire disease. Transl Cancer Res 2017; 6:S151-S157. PubMed
  • Rangachari D, VanderLaan PA, Shea M, Le X, Huberman MS, Kobayashi SS, Costa DB. Correlation between classic driver oncogene mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% expression in lung adenocarcinoma. J Thorac Oncol 2017. PubMed
  • Lucena-Araujo AR, Moran JP, VanderLaan PA, Dias-Santagata D, Folch E, Majid A, Kent MS, Gangadharan SP, Rangachari D, Huberman MS, Kobayashi SS, Costa DB. De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers. Lung Cancer 2016; 99:17-22. PubMed
  • Sheikine Y, Rangachari D, McDonald DC, Huberman MS, Folch ES, VanderLaan PA, Costa DB. EGFR Testing in Advanced Non-Small-Cell Lung Cancer, A Mini-Review. Clin Lung Cancer 2016. PubMed
  • Reiss KA, Rangachari D, Cosgrove D, Wilky B, Donehower R. Growing Pains: a Simulation-Based Curriculum for Improving the Transition to Hematology/Oncology Fellowship. J Cancer Educ 2016. PubMed
  • Rangachari D, Drake L, Huberman MS, McDonald DC, VanderLaan PA, Folch E, Costa DB. Rapidly fatal advanced EGFR-mutated lung cancers and the need for rapid tumor genotyping in clinical practice. Cancer Treat Commun 2016; 9:41-43. PubMed
  • Jorge SE, Schulman S, Freed JA, VanderLaan PA, Rangachari D, Kobayashi SS, Huberman MS, Costa DB. Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. Lung Cancer 2015; 90:369-74. PubMed
  • Shea M, Costa DB, Rangachari D. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. Ther Adv Respir Dis 2015. PubMed
  • Le X, Freed JA, VanderLaan PA, Huberman MS, Rangachari D, Jorge SE, Lucena-Araujo AR, Kobayashi SS, Balasubramanian S, He J, Chudnovsky Y, Miller VA, Ali SM, Costa DB. Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling. Clin Lung Cancer 2015. PubMed
  • Le X, Desai NV, Majid A, Karp RS, Huberman MS, Rangachari D, Kent MS, Gangadharan SP, Folch E, VanderLaan PA, Costa DB. De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors. Lung Cancer 2015. PubMed
  • Rangachari D, Yamaguchi N, VanderLaan PA, Folch E, Mahadevan A, Floyd SR, Uhlmann EJ, Wong ET, Dahlberg SE, Huberman MS, Costa DB. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer 2015. PubMed
  • Rangachari D, Brahmer JR. Targeting the immune system in the treatment of non-small-cell lung cancer. Curr Treat Options Oncol 2013; 14:580-94. PubMed
  • Arnaoutakis GJ, Rangachari D, Laheru DA, Iacobuzio-Donahue CA, Hruban RH, Herman JM, Edil BH, Pawlik TM, Schulick RD, Cameron JL, Meneshian A, Yang SC, Wolfgang CL. Pulmonary resection for isolated pancreatic adenocarcinoma metastasis: an analysis of outcomes and survival. J Gastrointest Surg 2011; 15:1611-7. PubMed
  • Rangachari D, VanderLaan PA, Le X, Folch E, Kent MS, Gangadharan SP, Majid A, Haspel RL, Joseph LJ, Huberman MS, Costa DB. Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice. Cancer Treat Commun ; 4:174-181. PubMed
  • Rangachari D, Smith TJ. Integrating palliative care in oncology: the oncologist as a primary palliative care provider. Cancer J ; 19:373-8. PubMed
  • Torous VF, Rangachari D, Gallant BP, Shea M, Costa DB, VanderLaan PA. PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option? J Am Soc Cytopathol ; 7:133-141. PubMed
Hide
Visualize Collaborations